How Portfolio Governance and PMOs Should Interact With CROs

A CRO cannot outperform the sponsor operating model it's beholden to. That's uncomfortable to say, but it's often true.

A CRO can have strong therapeutic expertise, an experienced study team, and sound processes and still struggle to deliver when sponsor priorities shift without clarity, decisions stall, or internal capacity stays invisible until it becomes a bottleneck.

CRO governance is typically backward-looking: KPI reviews, overdue actions, milestone explanations. Important, yes. But insufficient.

The question to ask: What made the milestone vulnerable, and what decision will protect the next one?

Asking that question is what turns the sponsor PMO into the connective tissue between portfolio strategy and operational delivery.

A strong PMO brings three lenses into CRO governance:

  • Resources: Are portfolio priorities, sponsor capacity, CRO staffing, and decision rights aligned or colliding?

  • Risk: Are clinical, regulatory, enrollment, and operational risks surfaced early enough to act on?

  • Forecasting: Do timelines, budgets, and scenarios reflect the real portfolio — not the version of it that existed at the last governance meeting?

Consider a typical "enrollment problem." It may reside on the CRO scorecard, but the underlying cause is often a sponsor reprioritization, an overextended internal SME, a late protocol decision, or competing demands across the portfolio. Another KPI won't fix that. A better sponsor-side operating model will.

Operational excellence does not include asking a CRO to work harder within a fragmented system.  But to enable operational excellence, the CRO/sponsor partnership has to work within a system designed to make good decisions early, manage trade-offs explicitly, and protect delivery.

That is the work: designing an operating model that connects portfolio governance, PMO insight, functional accountability, and CRO partnership management.

What would change if your CRO governance meetings focused less on explaining yesterday and more on protecting tomorrow? Let's talk.

If a CRO is underperforming the model it answers to, the model is the place to start. ABRA designs those: operating model and governance design.

Previous
Previous

What Fractional Executive Leadership Means for Emerging Biotech Sponsors

Next
Next

Outsourcing Model Choices: What Sponsors Often Get Wrong